Agios Other Operating Expenses from 2010 to 2024
| AGIO Stock | USD 58.66 0.44 0.74% |
Other Operating Expenses | First Reported 2011-12-31 | Previous Quarter 114.4 M | Current Value 111.8 M | Quarterly Volatility 42.9 M |
Check Agios Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharm's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 M, Interest Expense of 15.4 M or Selling General Administrative of 81.2 M, as well as many indicators such as Price To Sales Ratio of 32.17, Dividend Yield of 0.0 or PTB Ratio of 1.45. Agios financial statements analysis is a perfect complement when working with Agios Pharm Valuation or Volatility modules.
Agios | Other Operating Expenses |
Latest Agios Pharm's Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Agios Pharm over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Agios Pharm. It is also known as Agios Pharm overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Agios Pharm's Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Agios Pharm's overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Agios Other Operating Expenses Regression Statistics
| Arithmetic Mean | 277,584,166 | |
| Geometric Mean | 196,672,494 | |
| Coefficient Of Variation | 65.61 | |
| Mean Deviation | 158,057,888 | |
| Median | 321,831,485 | |
| Standard Deviation | 182,111,418 | |
| Sample Variance | 33164.6T | |
| Range | 505.8M | |
| R-Value | 0.83 | |
| Mean Square Error | 11374.4T | |
| R-Squared | 0.68 | |
| Significance | 0.0002 | |
| Slope | 33,617,419 | |
| Total Sum of Squares | 464304T |
Agios Other Operating Expenses History
About Agios Pharm Financial Statements
Agios Pharm investors utilize fundamental indicators, such as Other Operating Expenses, to predict how Agios Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 418.3 M | 321.8 M |
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Agios Stock
| 0.68 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Agios Stock
| 0.87 | PEPG | PepGen | PairCorr |
| 0.73 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.69 | PDSB | PDS Biotechnology Corp | PairCorr |
| 0.64 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.63 | MREO | Mereo BioPharma Group | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Agios Pharm Correlation against competitors. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.57 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.